Proinflammatory cytokine IL-6 -174G/C (rs1800795) gene polymorphism among patients with chronic renal failure // Polimorfismo del gen de la citosina IL-6 pro inflamatoria en pacientes con insuficiencia renal crónica

Sarhang H. Azeez, Suhaila N. Darogha

Resumen


Abstract

Interleukin-6 polymorphism is regarded as an aggravating factor in the development and progression of renal disease. IL-6-174G/C (rs1800795) genotypes are associated with increased risk of cardiovascular events in patients receiving hemodialysis. The aim of this study was to determine the relation between IL-6 gene polymorphism in patients with chronic kidney disease, in an Iraqi Kurdish population. IL-6 polymorphism at -174G/C (rs1800795) was assessed in 108 patients with chronic kidney disease (54 on hemodialysis and 54 renal transplanted) and 54 healthy subjects. The mean ages were 46.1, 36.8, and 40.2 for the hemodialysis patients, renal transplanted and healthy subjects, respectively. In the hemodialysis patients, GC intermediate producers were found at a double-fold higher risk of progression of the disease. Allele frequency G was 0.66 and 0.74 for the patients and the control group, respectively. While for renal transplanted patients, GG high producers were lower than the control group. GC genotype was one-and-half-fold higher for the renal transplanted patients than the control group. Levels of serum IL-6 increased significantly in GG and GC genotypes between both patient groups (P<0.001). However, there was no significant difference between the patient and control groups in terms of their CC genotype (P>0.05). These findings support the hypothesis of the impact of IL-6 on the progression of chronic renal failure. The IL-6 -174G/C (rs1800795) polymorphism predicts the inflammatory status of the progressed disease, and has a significant effect on the level of pro-inflammatory cytokine IL-6 in end-stage renal disease patients.

Resumen

El polimorfismo de la interleucina-6 se considera un factor agravante en el desarrollo y la progresión de la enfermedad renal. Los genotipos de IL-6-174G / C se asocian con un mayor riesgo de eventos cardiovasculares en pacientes que reciben hemodiálisis. En este estudio se determinóla relación entre el polimorfismo del gen de la IL-6 y enfermedad renal crónica, en una población kurda iraquí. El polimorfismo de IL-6 a -174G/C se evaluó en 108 pacientes con enfermedad renal crónica (54 en hemodiálisis y 54 con trasplante renal) y en 54 sujetos sanos. En los pacientes en hemodiálisis, se encontró que los productores intermedios de GC tenían el doble de riesgo en la progresión de la enfermedad. La frecuencia alélica G fue de 0,66 y 0,74 para los pacientes y el grupo control, respectivamente. Mientras que, para los pacientes trasplantados renales, los productores con GG alto fueron menores que en el grupo de control. El genotipo de GC fue una vez y media más alto para los pacientes trasplantados renales que para los individuos sanos. El nivel de IL-6 sérica aumentó significativamente en los genotipos GG y GC entre ambos grupos de pacientes (P<0,001). Sin embargo, no hubo diferencias significativas entre los grupos de pacientes y de control en términos de su genotipo CC (P>0,05). Estos hallazgos apoyan la hipótesis del impacto de la IL-6 en la progresión de la insuficiencia renal crónica. El polimorfismo IL-6 (-174G/C) predice el estado inflamatorio de la enfermedad progresiva, y este polimorfismo tiene un efecto significativo en el nivel de la citoquina pro inflamatoria IL-6 en pacientes con enfermedad renal en etapa terminal.


Palabras clave


Interleukin-6; gene polymorphism; hemodialysis; renal transplantation // IL-6; polimorfismo génico; hemodiálisis; trasplante renal.

Texto completo:

PDF

Referencias


Harun UR.Management of end stage renal disease-Bangladesh perspective. The Open Uro Nephrol J 2014; 7: 108-111.

Cibulka R, Racek J.Metabolic disorders in patients with chronic kidney failure. Physiol Res 2007; 56: 697-705.

Choi HY, Park HC, Ha SK.How do we manage coronary artery disease in patients with CKD and ESRD? Electrolyte & blood pressure 2014; 12(2): 41-54.

Ghaderian SB, Hayati F, Shayanpour S, Beladi Mousavi SS.Diabetes and end-stage renal disease; a review article on new concepts. J Ren Inj Prev 2015; 4(2): 28-33.

Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003; 361:327–333.

Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease—No longer a simple plumbing problem. J Am Soc Nephrol 2003; 14:1927–1939.

Stenvinkel P, Alvestrand P.Inflammation in end-stage renal disease: Sources, consequences and therapy. Semin Dial 2002; 15:330–338.

Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Kalantar-Zadeh K. Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr 2011; 21:100-104.

McMaster, WG, Kirabo A, Madhur MS, Harrison DG.Inflammation, immunity, and hypertensive end-organ damage. Circ Res 2015; 116(6): 1022-1033.

Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 2005; 67:1216–1233.

Yao Q, Lindholm B, Stenvinkel P.Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8:118-129.

Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M.Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestations of the disease. Rheumatology 2001; 40:656-661.

Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64:616-622.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V.Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209–214.

Pecoits-Filho R, Barany P, Lindholm B, Heimbürger O, Stenvinkel P.Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684–1688.

Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 4:720-726.

Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DS.Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 2007; 72:549-556.

Mandić S, Sudarević B, Marczi S, Horvat V, Cosić I, Mihaljević S, Milicević N, Simunović D, Galić J. Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia. Coll Antropol 2013; 37:907-911.

Zhai K, Yang Y, Gao ZG, Ding J.Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer. Oncotarget 2017; 8(27):44490-44497.

Morgan L, Cooper J, Montgomery H, Kitchen N, Humphries SE.The interleukin-6 gene -174G>C and -572G>C promoter polymorphisms are related to cerebral aneurysms. J Neur Neurosur Psych 2006; 77(8), 915-927.

DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B. Interleukin-6 −174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63:8051– 8056.

Fishman D, Faulds G, Jeffery R, Mohamed-AliV, YudkinJS, HumphriesS, P WooP. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.

Ioannou K, Stel VS, Dounousi E, JagerKJ, PapagianniA, PappasK, SiamopoulosKC, ZoccaliC, Dimitrios TsakirisD.Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) Patients: A Longitudinal Study. PLoS One 2015; 10(9):e0138461.

Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kid Dis 2005; 45:324-333.

McInnes IB Schett G.Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429–442.

Allon M, Depnerta TA, Radeva M, Bailey J, Beddhu S, Butterly D, Coyne DW, Gassman JJ, Kaufman AM, Kaysen GA, Lewis JA, Schwab SJ. Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO study. J Am Soc Nephrol 2003; 14:1863–1870.

Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, Einollahi B. Immune disorders in hemodialysis patients. Iran J Kid Dis 2015; 9(2):84-96.

Gomes K.IL-6 and type 1 diabetes mellitus: T cell responses and increase in IL-6 receptor surface expression. Ann Transl Med 2017; 5(1), 16.

Mittal RD, Manchanda PK. Association of interleukin (IL)-4 intron-3 and IL-6 -174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics 2007; 59(2):159-165.

Marrone D, Pertosa G, Simone S, Loverre A, Capobianco C, Cifarelli M, Memoli B, Schena FP, Grandaliano G.Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis 2007; 49:664- 673.

Liu BC, Li L, Gao M, Wang YL, Yu JR. Microinflammation is involved in the dysfunction of arteriovenous fistula in patients with maintenance hemodialysis. Chin Med J (Engl) 2008; 121:2157-2161.

Aker S, Bantis C, Reis P, Kuhr N, Schwandt C, Grabensee B, Heering P, Ivens K.Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Neph Dial Trans 2009; 24:9:2847–2851.

Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yno M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura N, Yoshigawa T.Interleukin-6 polymorphism (-634 C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002; 19:1000-1005.

Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res 2007; 150:101-105.

Ryu JH, Kim SJ.Interleukin-6 -634 C/G and -174 G/C polymorphisms in Korean patients undergoing hemodialysis. Kor J Inter Med 2012; 27(3), 327-337.

Mandal S, Abebe F, Chaudhary J.174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Gene Mol Res GMR 2014; 13(1), 139-151.

Nickel NP, O’Leary JM, Brittain E L, Fessel JP, Zamanian RT, West JD, & Austin ED. Kidney dysfunction in patients with pulmonary arterial hypertension. Pul Circ 2017; 7(1), 38-54.

Zhang J, Alcaide P, Liu L, Sun J, He A, Luscinskas FW, Shi GP. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One 2011; 6(1): e14525.

Chae MS, Moon KU, Chung HS, Park CS, Lee J, Choi JH, Hong SH.Serum interleukin-6 and tumor necrosis factor-αare associated with early graft regeneration after living donor liver transplantation. PLoS One. 2018; 13(4):e0195262.

Jones SA, Fraser DJ, Fielding CA, Jones GW. Interleukin-6 in renal disease and therapy. Nephr Dial Transpl 2015: (30); 1: 564-574.

Su H, Lei CT, Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Fron Immun 2017; 8: 405.

Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003; 23: 174–183.

Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB, Noh H, Williams PF, Williams AJ, Davison S, Dorval M, Summers A, Williams JD, Bankart J, Davies SJ, Topley N.Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24: 2071–2080.

Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12):836-843.

Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93–100.

Beberashvili I, Sinuani I, Azar A, Yasur H, Shapiro G, Feldman L, Averbukh Z, Weissgarten J.IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6(9), 2253-2263.

Bolton Ch, Downs LG, Victory JG, , Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001; 16:1189–1197.

Kovesdy CP, Kalantar-Zadeh K.Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 2008; 17(4), 451-467.

Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 2000; 22:345–354.

Caglar K, Peng Y, Pupim L, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA.Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62:1408–1416.

Shi C, Zhu L, Chen X, Gu N, Chen L, Zhu L, Yang L, Pang L, Guo X, Ji C, Zhang C. IL-6 and TNF-αinduced obesity-related inflammatory response through transcriptional regulation of miR-146b. J Interf Cytok Res 2014; 34(5), 342-348.

Axelsson J, Qureshi Ar, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, Lindholm B, Cederholm T, Stenvinkel P. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80:1222–1229.

Buraczynska M, Zukowski P, Ksiazek P, Kuczmaszewska A, Janicka J, Zaluska W.Transcription factor 7-like 2 (TCF7L2) gene polymorphism and clinical phenotype in end-stage renal disease patients. Mol Bio Rep 2014; 41(6), 4063-4068.

Pálsson R, Patel, UD.Cardiovascular complications of diabetic kidney disease. Adv Chro Kid Dis 2014; 21(3), 273-280.

Senthilkumar GP, Anithalekshmi MS, Yasir M, Parameswaran S.Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. Diabetes Metab Syndr2018; 12(1):23-26.

Spoto B, Mattace-Raso F, Sijbrands E, Leonardis D, Testa A, Pisano A, Pizzini P, Cutrupi S, Parlongo R M, D’Arrigo G, Tripepi G, Mallamaci F, Zoccali C. Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD. Clin J Am Soc Neph 2014; 10(2), 232-240.

Merhi B, Bayliss G, Gohh RY.Role for urinary biomarkers in diagnosis of acute rejection in the transplanted kidney. Worl J Transp 2015; 5(4), 251-260.

Kazancioğlu R.Risk factors for chronic kidney disease: an update. Kidney Int 2013; 3(4):368-371.




Universidad del Zulia / Venezuela / Investigación Clínica /riclinicas@gmail.com / p-ISSN: 0535-5133 / e-ISSN: 2477-9393

ReviCyHLUZ

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 3.0 Unported.